Working Group on New TB Drugs Launches Strategic Plan 2011-2015

Click here to access publication.

The WGND Strategic Plan 2011-2015 is an update of the “New Drugs” section of the Global Plan to Stop TB: 2011-2015. It describes the progress, gaps, and vision of the WGND and the TB drug development field as a whole. Since its inception, the WGND has served as a venue for interaction among partners working in all stages of TB drug research and development, to increase efficiencies and decrease risk for the process as a whole. One of the lessons learned since the introduction of the existing anti-TB drugs is that continued multi-year worldwide commitment, research and vigilance to ensure a consistent pipeline of new antimicrobials will be required to eradicate TB in the 21st century. Thus, there is a need to sustain the critical collaborations between public and private partners to build the current portfolio, which have leveraged the scientific and clinical knowledge of industry, the public health sector, and world-wide academic laboratories. With its diverse membership, including representatives of all these constituencies, as well as regulators, representatives of affected communities and those in a position to provide funding and support, the WGND remains a unique mechanism for ensuring a consistent pipeline of drug candidates.

Click here to download the WGND Strategic Plan 2011-2015.

More News
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...
3 Aug 2023
The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...
23 Aug 2022
The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...